Related Experiment Video
Updated: Aug 19, 2026

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model
Published on: December 10, 2021
Case Report: Myocarditis After COVID-19 Vaccination - Case Series and Literature Review
Samuel Nunn1, Johannes Kersten1, Marijana Tadic1
1Department for Internal Medicine II, University of Ulm, Ulm, Germany.
Insights
Acute myocarditis is a rare side effect of mRNA vaccines. This case series highlights its diagnosis and confirms the vaccine
Area of Science:
- Cardiology
- Immunology
- Public Health
Background:
- COVID-19 pandemic necessitates widespread vaccination.
- mRNA vaccines are crucial for population immunity.
- Acute myocarditis is a rare adverse event associated with mRNA vaccines.
Observation:
- A case series of four patients (16-47 years old) presented with acute myocarditis/pericarditis.
- Symptoms included chest pain, fever, and flu-like illness, occurring 3-17 days post-mRNA vaccination.
- Diagnosis involved clinical presentation, elevated cardiac biomarkers (troponin T, NT-proBNP), echocardiography, and cardiovascular magnetic resonance imaging.
Findings:
- Multimodal diagnostic approaches confirmed acute myocarditis.
- Two patients underwent endomyocardial biopsies.
- Patients experienced a mild clinical course with rapid discharge, without cardiogenic shock.
Implications:
- Findings align with existing reports of post-vaccination myocarditis.
- Multimodal diagnostics are essential for accurate identification.
- The established risk-benefit profile favors mRNA vaccination over SARS-CoV-2 infection risks.
Background:
The ongoing COVID-19 pandemic demands a series of measures and, above all, the vaccination of a substantial proportion of the population. Acute myocarditis is a rare complication of the widely used mRNA-based vaccines.
Case Presentation:
We present a case series of four patients (three men and one woman, 16 to 47 years old) with acute pericarditis/myocarditis 3 to 17 days after mRNA vaccination. They presented with chest pain, fever, and flu-like symptoms. Diagnosis was made based on the synopsis of clinical presentation, elevated levels of troponin T and NT-proBNP, impaired systolic function on echocardiography, and findings in non-invasive tissue characterization by cardiovascular magnetic resonance imaging. Two patients also underwent endomyocardial biopsies. As none of the patients showed signs of cardiogenic shock, they were discharged from ward care only a few days after their initial presentations.
Conclusions:
Our data are consistent with other case reports of myocarditis early after mRNA vaccination and demonstrate the need for multimodal diagnostics. In view of its rarity and mild course, the risk-benefit ratio of vaccination remains positive compared to potential SARS-CoV-2 infection.
More Related Videos
Related Concept Videos
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Pericarditis I: Introduction
Pericarditis II: Clinical Features and Diagnostic Tests

